Improved Performance with Conversion from ELISA to an Erenna® Immunoassay

Improved Performance with Conversion from ELISA to an Erenna® Immunoassay

1 Feb 2016

This application note from EMD Millipore demonstrates the Erenna Immunoassay System as a system to quantify a target that using an ELISA technique was undetectable. The application note looks at benefits of different techniques to decide which technique is best for results and cost effective.

High-Definition Erenna® Immunoassay System

Merck

The Erenna Immunoassay System, powered by Singulex's patented single-molecule detection technology, accelerates biomedical and translational research by accurately and reliably quantifying low-abundance biomarkers at or below sub-picogram concentrations. This unique high-definition technology enables distinct stratification of healthy and disease subjects through a broad dynamic range of over 4 logs, enhancing the clinical utility of biomarkers and allowing researchers to gain insights into drug safety and efficacy. The Erenna Immunoassay System includes fully equipped benchtop analytical instrumentation, integrated and prepared reagents for ultrasensitive immunoassays, and dedicated software to automatically analyze data and display detailed assay reports. The Erenna Immunoassay System uses a robust digital molecule-counting module to count photons, where ultra-sensitive fluorescence is measured in the presence of proprietary background reduction methodology. A large dynamic range of 4+ logs is obtained by combining single-molecule counting (low range) with photon counting (mid range) and total light measurements (high range).

(1)

Links

Tags

Improved Performance with Conversion from ELISA to an Erenna® Immunoassay